Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

RNA interference as therapeutics for hepatocellular carcinoma.

Xu C, Lee SA, Chen X.

Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):106-15. Review.

PMID:
21110827
2.

RNA interference-mediated prevention and therapy for hepatocellular carcinoma.

Romano PR, McCallus DE, Pachuk CJ.

Oncogene. 2006 Jun 26;25(27):3857-65. Review.

PMID:
16799627
3.

Gene therapy strategies for hepatocellular carcinoma.

Hwang LH.

J Biomed Sci. 2006 Jul;13(4):453-68. Epub 2006 Apr 22. Review.

PMID:
16633742
4.

[Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference].

Zhang PH, Tu ZG, Yang MQ, Huang WF, Zou L, Zhou YL.

Ai Zheng. 2004 Jun;23(6):619-25. Chinese.

PMID:
15191658
5.

The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.

Marotta F, Vangieri B, Cecere A, Gattoni A.

Clin Ter. 2004 May;155(5):187-99. Review.

PMID:
15344567
6.

[Experimental research of therapeutic effect on hepatocellular carcinoma of targeting SMYD3 gene inhibition by RNA interference].

Xu JY, Chen LB, Xu JY, Yang Z, Xu RH, Wei HY.

Zhonghua Wai Ke Za Zhi. 2006 Apr 1;44(7):481-4. Chinese.

PMID:
16772086
7.

Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Arbuthnot P, Thompson LJ.

World J Gastroenterol. 2008 Mar 21;14(11):1670-81. Review.

8.

Therapeutic strategies for hepatitis B virus-associated hepatocellular carcinoma.

Wong ET, Chew YP, Lee LA, Lee CG.

Curr Drug Targets. 2002 Oct;3(5):369-78. Review.

PMID:
12182228
9.

Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma.

Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H, Wu M, Wang H.

Gastroenterology. 2005 Jun;128(7):2029-41.

PMID:
15940635
10.

Molecular therapy and prevention of hepatocellular carcinoma.

Blum HE.

Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):11-22. Review.

11.

DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control.

Chang PC, Chi CW, Chau GY, Li FY, Tsai YH, Wu JC, Wu Lee YH.

Oncogene. 2006 Mar 30;25(14):1991-2003.

PMID:
16301996
12.

EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma.

Chen G, Wang Y, Zhou M, Shi H, Yu Z, Zhu Y, Yu F.

Oncol Rep. 2010 Feb;23(2):563-70.

PMID:
20043122
13.

Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma.

Farra R, Grassi M, Grassi G, Dapas B.

World J Gastroenterol. 2015 Aug 14;21(30):8994-9001. doi: 10.3748/wjg.v21.i30.8994. Review.

14.

Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.

Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR.

BMC Cancer. 2006 Oct 2;6:232.

15.

Hepatocellular carcinoma: are we making progress?

Zhu AX.

Cancer Invest. 2003 Jun;21(3):418-28. Review.

PMID:
12901288
16.

RecQL1 DNA repair helicase: A potential tumor marker and therapeutic target against hepatocellular carcinoma.

Futami K, Ogasawara S, Goto H, Yano H, Furuichi Y.

Int J Mol Med. 2010 Apr;25(4):537-45.

PMID:
20198302
17.

Central genetic alterations common to all HCV-positive, HBV-positive and non-B, non-C hepatocellular carcinoma: a new approach to identify novel tumor markers.

Kurokawa Y, Honma K, Takemasa I, Nakamori S, Kita-Matsuo H, Motoori M, Nagano H, Dono K, Ochiya T, Monden M, Kato K.

Int J Oncol. 2006 Feb;28(2):383-91.

PMID:
16391793
18.

Gene therapy for malignant liver disease.

Mohr L, Geissler M, Blum HE.

Expert Opin Biol Ther. 2002 Feb;2(2):163-75. Review.

PMID:
11849116
19.

Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes.

Cho HA, Park IS, Kim TW, Oh YK, Yang KS, Kim JS.

Arch Pharm Res. 2009 Jul;32(7):1077-86. doi: 10.1007/s12272-009-1714-z. Epub 2009 Jul 31.

PMID:
19641890
20.

Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome.

Herceg Z, Paliwal A.

Mutat Res. 2011 May-Jun;727(3):55-61. doi: 10.1016/j.mrrev.2011.04.001. Epub 2011 Apr 15. Review.

PMID:
21514401

Supplemental Content

Support Center